Talecris Earnings Rise on Stronger Blood Therapeutics Sales

Talecris Biotherapeutics, whose $3.4 billion acquisition by Spanish company Grifols is still pending regulatory approval, released financial results Wednesday showing fourth-quarter profit of $17.1 million, up from $1.4 million a year ago.
Med City